CompletedNot Applicable

Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO

United States223 participantsStarted 2017-06-22

Plain-language summary

The primary objective of the study is to estimate the proportion of carcinoid syndrome (CS) patients who are satisfied with their overall symptom control, 6 months after initiating treatment with telotristat ethyl (XERMELO).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult, ≥18 years of age at the time of informed consent * A new, valid prescription for XERMELO * Initiating XERMELO for the treatment of carcinoid syndrome * Able and willing to provide informed consent prior to participation in the study Exclusion Criteria: * Unable to understand and read English * Unable to access the internet * Prior exposure to XERMELO

What they're measuring

Percentage of Patients Who Are Satisfied With Their Overall Symptom Control

Timeframe: Baseline to 6 months

Trial details

NCT IDNCT03223428

SponsorTerSera Therapeutics LLC

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2022-01-14

Results submitted2023-04-19

View on ClinicalTrials.gov More Carcinoid Syndrome trials